Back to search
Cancer Therapy-Related Cardiac Dysfunction
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Cancer Therapy-Related Cardiac Dysfunction trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Cancer Therapy-Related Cardiac Dysfunction trials you may qualify forCancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cance…
Cancer treatments have improved substantially over the past decades, but some effective therapies such as anthracyclines and HER2-targeted agents are associated…
To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 3…
Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more…
Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis. There is increased risk fo…
Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk f…
This study investigates the use of AI-enhanced electrocardiogram (ECG) for risk stratification of cancer therapy-related cardiac dysfunction (CTRCD) before the…
This is an observational study that includes patients with breast cancer or non-small cell lung cancer who will be treated with immune checkpoint inhibitor (ICI…
This study, called "ROSUBREAST", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart i…